Stockholm - Delayed Quote SEK

Mendus AB (publ) (IMMU.ST)

0.4700

-0.0200

(-4.08%)

At close: April 25 at 5:29 PM GMT+2

Mendus to present NK cell program progress at the Innate Killer Summit

Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present the progress of its NK cell program at the 9th Annual Innate Killer Cell Summit, a leading conference for NK cell-based therapies. Mendus Director of Research Satwinder Kaur Singh, PhD will be expert speaker at the 9th Annual Innate Killer Summit held March 18-20 in San Diego, CA, USA. The Innate Kil

GlobeNewswire last month

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3

Press Release Stockholm, Sweden, March 15, 2024 Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company’s major shareholders, holding approximately 65.8 percent of shares in the Company, declare their intention to exercise warrants of series TO3 (the “Warrants”) to subscribe for newly issued shares corresponding to their holdings of Warrants during the subscription period 15-29 March 2024 at the subscription price of 0.48 SEK per share. The major sha

GlobeNewswire last month

IMMU-TO3.ST

IMMU.ST
-4.08%
The exercise period for warrants of series TO3 commences today

Press Release Stockholm, Sweden, March 15, 2024 On June 8, 2023, Mendus AB (publ) (“Mendus” or the “Company”), (NASDAQ Stockholm: IMMU), announced that the Board of Directors had resolved on a capital raise of approximately SEK 317 million (the “Transaction”), comprised of a directed issue of shares and warrants to Flerie Invest AB of approximately SEK 90 million (the “Directed Issue”), in combination with a fully secured rights issue of units of approximately SEK 227 million (the “Rights Issue”

GlobeNewswire last month

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus provides business update and outlook for vididencel program

Press Release Stockholm, Sweden, March 12, 2024 ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemiaRegistration trial preparations are ongoing, following positive initial FDA feedback on main questions related to late-stage clinical development and large-scale manufacturingManufacturing alliance with NorthX Biologics on track, with production facility installed and tech transfer process for large-scale GMP manufacturing of v

GlobeNewswire last month

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus to participate in upcoming industry conferences

Press release Stockholm, Sweden, February 27, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming industry conferences: 10th annual IO360° Summit New York, USA, February 27-29, 2024 CEO Erik Manting will participate in the 10th annual IO360° Summit, a conference dedicated to reporting on the latest advancements and data in Immuno-Oncology. https://io360summi

GlobeNewswire last month

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus to hold Business Update event on March 12

Press Release Stockholm, Sweden, February 23, 2024 Mendus AB (“Mendus” publ; IMMU.ST), will hold an in-person and live-streamed business update event in Stockholm on March 12, 15:00-17:00 CET to discuss the company’s latest pipeline advancements. Mendus has recently presented positive Phase 2 data with vididencel in acute myeloid leukemia (AML), an aggressive blood-borne tumor associated with high relapse rates, at the ASH 2023 conference. Vididencel addresses the need for safe and effective AML

GlobeNewswire 2 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus AB Year-end Report for 2023

Press Release Stockholm, Sweden, February 14, 2024 Positive ADVANCE II data at ASH caps strong 2023 The fourth quarter of 2023 closes a crucial year for Mendus and delivered additional milestones to further strengthen the development of our lead product vididencel as a novel maintenance treatment for acute myeloid leukemia (AML). Mendus is at an exciting point in its journey, supported by continued positive clinical data confirming the potential of vididencel to significantly improve disease-fre

GlobeNewswire 2 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Invitation to presentation of Mendus’ year-end report for 2023

Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2023 on Wednesday 14 February 2024 at 08:00 CET. The company will hold a conference call and an online presentation on the same day at 10:00 CET. The call will be hosted by CEO Erik Manting. The presentation will be in English and followed by a question-and-answer session. Listen to the presentation webcast: https://ir.financialhearings.com/mendus-q4-2023 Please send any questions ahead of the presentation to ir@mendus.com

GlobeNewswire 2 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus to participate in several investor and industry conferences in January

Press release Stockholm, Sweden, January 8, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences: 42nd Annual J.P. Morgan Healthcare Conference San Francisco, USA, January 8-11, 2024 Mendus management team will be in San Francisco for business and investor meetings during the J.P, Morgan conference https://www.jpmorgan.com/ab

GlobeNewswire 3 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus announces clinical pipeline update

Press Release Stockholm, Sweden, December 22, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announced an update on the status and outlook of its clinical pipeline programs. Mendus reports completion of the long-term follow up of the MERECA trial studying the intratumoral immune primer ilixadencel in metastatic renal cell carcinoma (mRCC). The long-term follow up data confirmed the observations previously reported, wit

GlobeNewswire 4 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus AB: REPORT FROM THE EXTRAORDINARY GENERAL MEETING OF MENDUS AB (PUBL) ON 13 DECEMBER 2023

Press Release Stockholm, Sweden, December 13, 2023 At the extraordinary general meeting (the “EGM”) of Mendus AB (publ), reg. no. 556629-1786, (the “Company”), on 13 December 2023 the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the meeting and the complete proposals for resolutions, which have previously been published and are available on the Company’s website, www.mendus.com Election

GlobeNewswire 4 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023

Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival (mRFS) stood at 30.4 months Median overall survival (mOS) was not reached, with the majority of patients (14/20) still aliveReduction in measurable residual disease (MRD) and induction of immune responses correlate with RFS and OS benefit, confirming vididencel mechanism of actionVirtual KOL event with principal investigator to discuss new ASH data on Thursday, December 14, 2023, at 9.00 am E

GlobeNewswire 4 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML

Press Release Stockholm, Sweden, December 6, 2023 CADENCE Phase 2 trial will evaluate vididencel in combination with oral azacitidineRandomized controlled trial in 40 patients, with potential to extend up to 140 patientsCollaboration with ALLG to significantly strengthen Mendus clinical trial network Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the company has entered into a collaboration with the Aus

GlobeNewswire 4 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6

Press Release Stockholm, Sweden, December 5, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced it will present the development of a robust, scaled up industrial process for vididencel supply at the Cell & Gene Therapy Manufacturing & Commercialization Conference held Dec 4-6 in Dublin. Mendus Chief Technology Officer Leopold Bertea will chair the Cell Therapy Manufacturing & Analytics session on Dec 5 and

GlobeNewswire 4 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023

Press Release Stockholm, Sweden, December 4, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced it will host a virtual KOL Event on December 14, 2023 at 9:00 AM ET, featuring Dr. Arjan van de Loosdrecht, Professor of Hematology at Amsterdam UMC and Principal Investigator of the ADVANCE II trial, who will discuss the current treatment landscape for patients with Acute Myeloid Leukemia (AML) and the developme

GlobeNewswire 4 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus Announces Nomination Committee for the 2024 Annual General Meeting

Press Release Stockholm, Sweden, November 17, 2023 Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee have been appointed in accordance with the principles for appointment of the Nomination Committee, adopted by the Annual General Meeting of May 4, 2021. The members of Mendus’ Nomination Committee shall be appointed by the four largest shareholders, as of August 31, 2023, who wish to exercise their right to appoint a representative. If four shareholders have n

GlobeNewswire 5 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
NOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL)

Press Release Stockholm, Sweden, November 13, 2023 The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Extraordinary General Meeting (“EGM”) on Wednesday, 13 December 2023, at 16:00, at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm. Registration for the meeting will commence at 15:30. NOTIFICATION Shareholders who wish to attend the meeting must: (i) both be recorded in the share register maintained by Euroclear Sweden AB on the record d

GlobeNewswire 5 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus AB Interim Report January – September 2023

Press Release Stockholm, Sweden, November 9, 2023 So far in 2023, Mendus has realized significant progress in its corporate development, and we aim to end the year strong The progress made in the previous quarters provided the basis for a financing round which we completed in July, to support the next stage of our corporate development. The directed placement and rights issue totaling SEK 317M supports further read-outs of the ongoing ADVANCE II and ALISON vididencel trials, the start of new cli

GlobeNewswire 5 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023

Press Release Stockholm, Sweden, November 6, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the publication of updated clinical data from the ongoing ALISON Phase 1 trial with the company’s lead program vididencel at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, the largest conference for cancer immunotherapy. The data demonstrate the boosting of broad immune responses in the maj

GlobeNewswire 5 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%
Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal

Press Release Stockholm, Sweden, November 3, 2023 Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal Publication provides additional clinical evidence that vididencel has strong potential as a new maintenance therapy in AML and high-risk MDS patientsPatients with low disease burden have the best chance to respond to vididencel treatment, supporting the maintenance therapy setting currently pursued in the ADVANCE II Phase

GlobeNewswire 5 months ago

IMMU-TO3.ST

IMMU.ST
-4.08%

Performance Overview

Return	IMMU.ST	OMX Stockholm 30 Index
YTD	-10.13%	+5.31%
1-Year	-71.65%	+11.75%
3-Year	-90.50%	+12.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mendus AB (publ) (IMMU.ST)

Mendus to present NK cell program progress at the Innate Killer Summit

Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3

The exercise period for warrants of series TO3 commences today

Mendus provides business update and outlook for vididencel program

Mendus to participate in upcoming industry conferences

Mendus to hold Business Update event on March 12

Mendus AB Year-end Report for 2023

Invitation to presentation of Mendus’ year-end report for 2023

Mendus to participate in several investor and industry conferences in January

Mendus announces clinical pipeline update

Mendus AB: REPORT FROM THE EXTRAORDINARY GENERAL MEETING OF MENDUS AB (PUBL) ON 13 DECEMBER 2023

Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023

Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML

Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6

Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023

Mendus Announces Nomination Committee for the 2024 Annual General Meeting

NOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL)

Mendus AB Interim Report January – September 2023

Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023

Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal

Performance Overview